organization · Reporting owner
Celgene Switzerland LLC
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | 10% owner | November 12, 2019 | November 14, 2019 |
| Jounce Therapeutics, Inc.JNCE · Entity 15754 | 10% owner | February 01, 2017 | February 01, 2017 |
| Juno Therapeutics, Inc.JUNO · Entity 168572 | 10% owner | March 05, 2018 | March 06, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date November 12, 2019 · Filed November 14, 2019
Jointly reported with CELGENE CORP /DE/, Celgene European Investment Co LLC, Celgene Alpine Investment Co., LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,777,824 |
Reported balance
After 2019-11-12 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-11-12 · Purchase · Acquired 403,225 · Balance 1,777,824 |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 624,575 |
Reported balance
Holding disclosure · report date 2019-11-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 624,575 F1: Owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene and the other reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 4,010,926 |
Reported balance
Holding disclosure · report date 2019-11-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,010,926 F2: Owned directly by Celgene European Investment Company LLC, a wholly-owned subsidiary of Celgene. Celgene and the other reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 708,333 |
Reported balance
Holding disclosure · report date 2019-11-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 708,333 F3: Owned directly by Celgene Alpine Investment Co., LLC, a wholly-owned subsidiary of Celgene. Celgene and the other reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene and the other reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
F2: Owned directly by Celgene European Investment Company LLC, a wholly-owned subsidiary of Celgene. Celgene and the other reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
F3: Owned directly by Celgene Alpine Investment Co., LLC, a wholly-owned subsidiary of Celgene. Celgene and the other reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
Jounce Therapeutics, Inc.
Report date February 01, 2017 · Filed February 01, 2017
Jointly reported with CELGENE CORP /DE/
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,456,463 |
Last balance in matching sequence
After 2017-02-01 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2017-02-01 · Conversion · Acquired 2,831,463 · Balance 2,831,463 F1: Upon closing of the Issuer's initial public offering, each share of Series B-1 Preferred Stock automatically converted into 0.271 share of Common Stock without payment of further consideration. The shares had no expiration date. F2: These shares are owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene"), and Celgene has the power to vote, acquire, hold and dispose of all shares. Celgene disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Row 2 · 2017-02-01 · Purchase · Acquired 625,000 · Balance 3,456,463 F2: These shares are owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene"), and Celgene has the power to vote, acquire, hold and dispose of all shares. Celgene disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. |
| Series B-1 Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-02-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-02-01 · Conversion · Disposed 10,448,100 · Balance 0 F1: Upon closing of the Issuer's initial public offering, each share of Series B-1 Preferred Stock automatically converted into 0.271 share of Common Stock without payment of further consideration. The shares had no expiration date. F2: These shares are owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene"), and Celgene has the power to vote, acquire, hold and dispose of all shares. Celgene disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon closing of the Issuer's initial public offering, each share of Series B-1 Preferred Stock automatically converted into 0.271 share of Common Stock without payment of further consideration. The shares had no expiration date.
F2: These shares are owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene"), and Celgene has the power to vote, acquire, hold and dispose of all shares. Celgene disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
Juno Therapeutics, Inc.
Report date March 05, 2018 · Filed March 06, 2018
Jointly reported with CELGENE CORP /DE/, Blue Magpie Corp
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 11,109,160 |
Reported balance
Holding disclosure · report date 2018-03-05 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 11,109,160 F1: These shares are owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene"). |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 88,118,707 |
Reported balance
Holding disclosure · report date 2018-03-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 88,118,707 F2: These shares are owned directly by Blue Magpie Corporation, a wholly-owned subsidiary of Celgene. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene").
F2: These shares are owned directly by Blue Magpie Corporation, a wholly-owned subsidiary of Celgene.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 12, 2019 Filed Nov 14, 2019 16:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | PurchaseCommon Stock | 403,225 | $31.00 | $12,499,975.00 |
DisclosureSEC source: 0001104659-19-064171 · tm1922788d1_4.xml · nonDerivative · entry 1 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner Celgene European Investment Co LLC · CIK 0001577650 · 10% owner Celgene Switzerland LLC · CIK 0001661486 · 10% owner Celgene Alpine Investment Co., LLC · CIK 0001581774 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,777,824 Read SEC document |
| January 23, 2018 Filed Jan 23, 2018 16:35 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | PurchaseCommon Stock | 851,154 | $67.00 | $57,027,318.00 |
DisclosureSEC source: 0001209191-18-004895 · doc4.xml · nonDerivative · entry 1 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner Celgene Switzerland LLC · CIK 0001661486 · 10% owner Celgene Alpine Investment Co., LLC · CIK 0001581774 · 10% owner Celgene European Investment Co LLC · CIK 0001577650 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,374,599 Read SEC document |
| January 23, 2018 Filed Jan 31, 2018 08:39 UTC Amendment | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | PurchaseCommon Stock | 851,154 | $67.00 | $57,027,318.00 |
DisclosureSEC source: 0001209191-18-006131 · doc4a.xml · nonDerivative · entry 1 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner Celgene Switzerland LLC · CIK 0001661486 · 10% owner Celgene Alpine Investment Co., LLC · CIK 0001581774 · 10% owner Celgene European Investment Co LLC · CIK 0001577650 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,374,599 F1 · date: This Form 4 Amendment is being submitted to correct the date of earliest transaction in box 3 to reflect January 23, 2018. Read SEC document |
| April 24, 2017 Filed Apr 24, 2017 16:34 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | PurchaseCommon Stock | 624,575 | $49.50 | $30,916,462.50 |
DisclosureSEC source: 0001209191-17-027983 · doc4.xml · nonDerivative · entry 1 Celgene European Investment Co LLC · CIK 0001577650 · 10% owner Celgene Switzerland LLC · CIK 0001661486 · 10% owner Celgene Alpine Investment Co., LLC · CIK 0001581774 · 10% owner CELGENE CORP /DE/ · CIK 0000816284 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,856,353 F1 · ownership.nature: Of these shares, 624,575 shares are owned directly by Celgene Switzerland LLC ("Celgene Switzerland"), 708,333 shares are owned directly by Celgene Alpine Investment Co. LLC ("Celgene Alpine"), each a wholly-owned subsidiary of Celgene Corporation ("Celgene"), and Celgene has the power to vote, acquire, hold and dispose of all such shares. Celgene and Celgene European Investment Company LLC, a wholly owned subsidiary of Celgene ("CEICO"), disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. The remaining 523,445 shares are owned directly by Celgene. CEICO, Celgene Switzerland and Celgene Alpine disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| February 01, 2017 Filed Feb 1, 2017 16:18 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | ConversionSeries B-1 Preferred Stock · Derivative | 10,448,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-006676 · doc4.xml · derivative · entry 3 Celgene Switzerland LLC · CIK 0001661486 · 10% owner CELGENE CORP /DE/ · CIK 0000816284 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,831,463 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of Series B-1 Preferred Stock automatically converted into 0.271 share of Common Stock without payment of further consideration. The shares had no expiration date. F1 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of Series B-1 Preferred Stock automatically converted into 0.271 share of Common Stock without payment of further consideration. The shares had no expiration date. F1 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of Series B-1 Preferred Stock automatically converted into 0.271 share of Common Stock without payment of further consideration. The shares had no expiration date. F2 · ownership.direct: These shares are owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene"), and Celgene has the power to vote, acquire, hold and dispose of all shares. Celgene disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| February 01, 2017 Filed Feb 1, 2017 16:18 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | PurchaseCommon Stock | 625,000 | $16.00 | $10,000,000.00 |
DisclosureSEC source: 0001209191-17-006676 · doc4.xml · nonDerivative · entry 2 Celgene Switzerland LLC · CIK 0001661486 · 10% owner CELGENE CORP /DE/ · CIK 0000816284 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,456,463 F2 · ownership.direct: These shares are owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene"), and Celgene has the power to vote, acquire, hold and dispose of all shares. Celgene disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| February 01, 2017 Filed Feb 1, 2017 16:18 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | ConversionCommon Stock | 2,831,463 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-006676 · doc4.xml · nonDerivative · entry 1 Celgene Switzerland LLC · CIK 0001661486 · 10% owner CELGENE CORP /DE/ · CIK 0000816284 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,831,463 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon closing of the Issuer's initial public offering, each share of Series B-1 Preferred Stock automatically converted into 0.271 share of Common Stock without payment of further consideration. The shares had no expiration date. F2 · ownership.direct: These shares are owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene"), and Celgene has the power to vote, acquire, hold and dispose of all shares. Celgene disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.